You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-CD41/Integrin alpha 2b antibody [M148] (FITC) (ab19708)

Overview

  • Product nameAnti-CD41/Integrin alpha 2b antibody [M148] (FITC)See all CD41/Integrin alpha 2b primary antibodies ...
  • Description
    Mouse monoclonal [M148] to CD41/Integrin alpha 2b (FITC)
  • ConjugationFITC
  • SpecificityRecognizes an epitope on the gpIIb/IIIa complex on the surface membrane of human platelets.
  • Tested applicationsFlow Cyt more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Human mededulloblastoma tissue

Properties

Applications

Our Abpromise guarantee covers the use of ab19708 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
Flow Cyt Flow Cyt: Use 1µg for 106 cells.

Target

  • FunctionIntegrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface.
  • Tissue specificityIsoform 1 and isoform 2 were identified in platelets and megakaryocytes, but not in reticulocytes or in Jurkat and U937 white blood cell line. Isoform 3 is expressed by leukemia, prostate adenocarcinoma and melanoma cells but not by platelets or normal prostate or breast epithelial cells.
  • Involvement in diseaseDefects in ITGA2B are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors.
  • Sequence similaritiesBelongs to the integrin alpha chain family.
    Contains 7 FG-GAP repeats.
  • Cellular localizationMembrane.
  • Target information above from: UniProt accession P08514 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      antigen CD41 antibodyBDPLT2 antibodyCD41 antibody
      cd41 antigen antibodyCD41a antibodycd41b antibodyform 2 antibodygp2b antibodyGPalpha IIb antibodygpalphaiib antibodygpiib antibodyGT antibodygta antibodyHPA3 antibodyIntegrin alpha 2b antibodyIntegrin alpha IIb antibodyIntegrin alpha-IIb light chain antibodyITA2B_HUMAN antibodyITGA2B antibodyITGAB antibodyplatelet fibrinogen receptor alpha antibodyplatelet fibrinogen receptor, alpha subunit antibodyplatelet glycoprotein IIb of IIb/IIIa complex antibodyplatelet membrane glycoprotein iib antibodyplatelet specific antigen bak antibody
    see all

References for Anti-CD41/Integrin alpha 2b antibody [M148] (FITC) (ab19708)

ab19708 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab19708.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"